AC Immune, developer of drugs against Alzheimer’s disease (ACIU.O) expects the number of families affected by the degenerative disease to nearly triple by 2050 to 150 million, its CEO said in an interview with a German magazine.
The company recently secured a multi-million dollar investment from major backers of German COVID-19 vaccine developer BioNTech (22UAy.DE) while acquiring a possible vaccine against Parkinson’s disease.
AC Immune CEO Andrea Pfeifer, in an interview with German business magazine Wirtschaftswoche published in its online edition on Sunday, described Alzheimer’s disease, an uncurable disease whose origin is unknown, as “a slow pandemic which is advancing towards the world”. It currently affects 55 million families, she said.
Athos, the holding company of Andreas and Thomas Struengmann – pillar investors of BioNTech (22UAy.DE) – With the finance companies, MIG and First Capital Partner jointly own 12% of AC Immune following an agreement reached a few weeks ago, Pfeifer said. The planned investment was announced in July.
Athos and MIG participated in the creation of BioNTech which, with its partner Pfizer (PFE.N) developed the most widely used COVID-19 vaccine in the Western world, and they remain the major shareholders.
Pfeifer said having the Struengmann twins on board was a “blessing” for AC Immune.
“If anyone knows how vaccines can be marketed, then these are the main investors in BioNTech,” she said.
AC Immune is working on several compounds for Alzheimer’s and Parkinson’s disease, including vaccines.
The company has yet to launch a drug.
The other investors in AC Immune are Dietmar Hopp through his biotech holding company Dievini with just over 20%, as well as institutional and private investors, Pfeifer said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.